Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBT (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EBT for 16 consecutive years, with -$651482.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 41.72% year-over-year to -$651482.0, compared with a TTM value of -$3.2 million through Sep 2025, up 32.76%, and an annual FY2024 reading of -$4.7 million, down 53.84% over the prior year.
  • EBT was -$651482.0 for Q3 2025 at China Pharma Holdings, down from -$528367.0 in the prior quarter.
  • Across five years, EBT topped out at -$475976.0 in Q1 2023 and bottomed at -$1.4 million in Q2 2024.
  • Average EBT over 5 years is -$902785.3, with a median of -$826669.0 recorded in 2021.
  • The sharpest move saw EBT crashed 6418.56% in 2021, then surged 63.26% in 2025.
  • Year by year, EBT stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then surged by 46.79% to -$651482.0 in 2025.
  • Business Quant data shows EBT for CPHI at -$651482.0 in Q3 2025, -$528367.0 in Q2 2025, and -$785572.0 in Q1 2025.